**Knowledge Check for eModule 2: Prevenar 13®** **(pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): The background**

This knowledge check consists of 10 questions, and should take a maximum of 15 minutes to complete.

Please read each question carefully, as the type of answer you need to give may vary.

Good luck.

This knowledge check is provided to you by Pfizer Ltd. The information covered is not intended to replace your guidelines, protocols and SOPs.

**Please note that the correct answer(s) to each question is in red.**

## Question 1

**Select the correct answer**

**The polysaccharides used in pneumococcal vaccines are obtained from which part of the *Streptococcus pneumoniae* bacteria?**

1. The capsule
2. The cytoplasm
3. The ribosomes
4. The cell membrane

Reference:

Public Health England. The Green Book [2018]. Chapter 25: Pneumococcal. Available at <https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25>.

Last accessed January 2020

## Question 2

**True or false**

**Prevenar 13® is the only pneumococcal conjugate vaccine licensed for adults.**

* True
* False

References:

Prevenar 13® Summary of Product Characteristics. June 2019.

Synflorix Summary of Product Characteristics. November 2018.

## Question 3

**Select all that apply**

**Conjugate vaccines…**

1. Involve the binding of polysaccharide antigens to a carrier protein
2. Are able to stimulate the pathways necessary to develop immune memory
3. Never require bacterial polysaccharides
4. Can provide lasting protection

References:

Public Health England. The Green Book [2018]. Chapter 1: Immunity and how vaccines work. Available at <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/144249/Green-Book-Chapter-1.pdf>. Last accessed January 2020

Pollard AJ, et al. Maintaining protection against invasive bacteria with protein polysaccharide vaccines. Nat Rev Immunol. 2009;9:213-220.

Goldblatt D. Conjugate vaccines. Clin Exp Immunol. 2000;119:1-3.

## Question 4

**Select all that apply**

**Prevenar 13® clinical trials…**

1. Have shown that Prevenar 13® is clinically proven to help prevent pneumococcal pneumonia in adults vs. placebo
2. Include a large-scale efficacy trial, which involved 84,496 subjects ≥65 years of age
3. Have shown that efficacy of Prevenar 13® vs. placebo persisted throughout a 4-year trial (post-hoc analysis)
4. Have shown that Prevenar 13® can generate a functional antibody response regardless of age

Prevenar 13® will only protect against *Streptococcus pneumoniae* serotypes included in the vaccine.

References:

Prevenar 13® Summary of Product Characteristics. June 2019.

Bonten MJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125.

## Question 5

**True or false**

**For adults aged 18 years or older, headache, chills and fatigue are all common or very common adverse reactions reported in Prevenar 13® clinical trials.**

* True
* False

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 6

**Select the correct answer**

**In adults, Prevenar 13® should generally be given…**

1. Intramuscularly as a single 0.5 ml dose
2. Intramuscularly as a course of three x 0.5 ml doses
3. Intravenously as a single 0.5 ml dose
4. Intravenously as a course of three x 0.5 ml doses

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 7

**Select the correct answer**

**Using only the information supplied below, who is not contraindicated to receive Prevenar 13®?**

1. Andy, who is hypersensitive to diphtheria toxoid
2. Alex, who is hypersensitive to Polysorbate 80
3. Nina, who has a cold
4. Jess, who is pregnant

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 8

**True or False**

**Adults can receive Prevenar 13® with the flu vaccine (trivalent and quadrivalent).**

* True
* False

Reference:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 9

**True or False**

**It is recommended that if a pneumococcal polysaccharide vaccine (PPV) and Prevenar 13® are both administered to the same person, Prevenar 13® should be given first.**

* True
* False

References:

Prevenar 13® Summary of Product Characteristics. June 2019.

## Question 10

**Select all that apply**

**Prevenar 13® does notcontain…**

1. Nut-derived ingredients
2. Egg-derived ingredients
3. The mercury-based preservative thiomersal
4. Formaldehyde
5. Aluminum phosphate

Pfizer cannot guarantee that individual vaccines have never come into contact with specific allergens.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

References:

Prevenar 13® Summary of Product Characteristics. June 2019.

Pfizer. Data on File. Ingredients. January 2015.

**Additional information:** In pneumococcal-vaccine naïve adults aged 18-49 years, percentages of solicited local and systemic reactions were generally higher compared with older subjects (aged 50-59 and 60-64 years).

